|Bid||41.74 x 1800|
|Ask||41.80 x 3000|
|Day's Range||41.42 - 41.83|
|52 Week Range||32.83 - 43.08|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||21.11|
|Earnings Date||Jul. 26, 2021 - Jul. 30, 2021|
|Forward Dividend & Yield||1.56 (3.98%)|
|Ex-Dividend Date||Jul. 29, 2021|
|1y Target Est||42.97|
South Korea kicked off COVID-19 vaccinations for people ages 55-59 on Monday to speed up the pace of its inoculation campaign, as the country battles the fourth wave of infections. The rollout of COVID-19 vaccinations for people in their upper 50s had sputtered to a week-long halt this month after a record high number of new cases sparked a rush for shots, exhausting available supplies and crashing an official reservation website.. About 6.17 million people, or 84% of those in their 50s, have signed up for vaccinations last week, and authorities switched to Pfizer/BioNTech's COVID-19 vaccine from Moderna shot for some people in the group because of fluctuations in shipment schedule.
Here are three value stocks to buy for the second half of 2021. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. The company's revenue grew 51% year over year in the first quarter of 2021.
It's fair to say that Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are dominating the coronavirus vaccine market these days. Their vaccines have fully immunized 86 million and 62 million Americans, respectively.